Biogen
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
CEOChristopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees7,570
Employees7,570
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded1978
Founded1978
Employees7,570
Employees7,570
BIIB Key Statistics
Market cap31.89B
Market cap31.89B
Price-Earnings ratio27.50
Price-Earnings ratio27.50
Dividend yield—
Dividend yield—
Average volume1.43M
Average volume1.43M
High today$220.56
High today$220.56
Low today$217.64
Low today$217.64
Open price$220.34
Open price$220.34
Volume1.33M
Volume1.33M
52 Week high$319.76
52 Week high$319.76
52 Week low$215.35
52 Week low$215.35
BIIB News
Benzinga 14h
Spotlight on Biogen: Analyzing the Surge in Options Activity - Biogen - BenzingaLoading... Loading... Investors with a lot of money to spend have taken a bullish stance on Biogen BIIB. And retail traders should know. We noticed this toda...
Yahoo Finance 5d
Why Is Biogen Inc. Up 2.6% Since Last Earnings Report? - Yahoo FinanceIt has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have added about 2.6% in that time frame, underperforming the S&P 500....
Yahoo Finance 7d
Biogen Inc. Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo FinanceIn the latest market close, Biogen Inc. (BIIB) reached $227.36, with a -1.18% movement compared to the previous day. This move lagged the S&P 500's daily gain o...
Analyst ratings
74%
of 35 ratingsBuy
74.3%
Hold
25.7%
Sell
0%